Mitchell V. Hull
Scripps Research Institute
9 Papers
4 Citations
Mitchell V. Hull is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Drug repositioning & Benznidazole. The author has an hindex of 5, co-authored 9 publications. Previous affiliations of Mitchell V. Hull include Scripps Health.
Chat about Author
Papers
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Malina A. Bakowski,Nathan Beutler,Karen C. Wolff,Melanie G. Kirkpatrick,Emily I. Chen,Tu-Trinh Nguyen,Laura Riva,Namir Shaabani,Mara Parren,James Ricketts,Anil Gupta,Kastin Pan,Peiting Kuo,MacKenzie Fuller,Elijah Garcia,John R. Teijaro,Linlin Yang,Debashis Sahoo,Victor Chi,Edward Huang,Natalia Vargas,Amanda J. Roberts,Soumita Das,Pradipta Ghosh,Ashley K. Woods,Sean B. Joseph,Mitchell V. Hull,Peter G. Schultz,Dennis R. Burton,Arnab K. Chatterjee,Case W. McNamara,Thomas F. Rogers,Thomas F. Rogers +32 more
TL;DR: In this article, the authors describe a screening pipeline for the discovery of efficacious SARS-CoV-2 inhibitors, and identify 49 (in HeLa-ACE2) and 41 (in Calu-3) compounds capable of selectively inhibiting SARS co-virus 2 replication.
Selective BET bromodomain inhibition as an antifungal therapeutic strategy.
Flore Mietton,Elena Ferri,Morgane Champleboux,Ninon Zala,Danièle Maubon,Yingsheng Zhou,Michael B. Harbut,Didier Spittler,Cécile Garnaud,Marie Courçon,Murielle Chauvel,Christophe d'Enfert,Boris A. Kashemirov,Mitchell V. Hull,Muriel Cornet,Charles E. McKenna,Jérôme Govin,Carlo Petosa +17 more
TL;DR: It is shown that the BET protein Bdf1 is essential in C. albicans and that mutations inactivating its two BDs result in a loss of viability in vitro and decreased virulence in mice, which establishes BET inhibition as a promising antifungal therapeutic strategy and identifies BDF1 as an antIfungal drug target that can be selectively inhibited without antagonizing human BET function.
Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19
Malina A. Bakowski,Nathan Beutler,Emily I. Chen,Tu-Trinh Nguyen,Melanie G. Kirkpatrick,Mara Parren,Linlin Yang,James Ricketts,Anil Gupta,Mitchell V. Hull,Peter G. Schultz,Dennis R. Burton,Arnab K. Chatterjee,Case W. McNamara,Thomas F. Rogers,Thomas F. Rogers +15 more
TL;DR: From nearly 12,000 compounds, 66 compounds capable of selectively inhibiting SARS-CoV-2 replication in human cells are identified and 24 of these drugs show additive activity in combination with the RNA-dependent RNA polymerase inhibitor remdesivir and may afford increased in vivo efficacy.
24
High-throughput screening of the ReFRAME library identifies potential drug repurposing candidates for Trypanosoma cruzi
Jean A. Bernatchez,Jean A. Bernatchez,Emily Chen,Mitchell V. Hull,Case W. McNamara,James H. McKerrow,James H. McKerrow,Jair L. Siqueira-Neto,Jair L. Siqueira-Neto +8 more
TL;DR: 7 compounds of interest are identified with potent in vitro activity against the parasite with a therapeutic index of 10 or greater, including the previously-unreported activity of the antiherpetic compound 348U87, which provides the framework for further development of new T. cruzi leads that can potentially move quickly to the clinic.
High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi.
Jean A. Bernatchez,Jean A. Bernatchez,Emily Chen,Mitchell V. Hull,Case W. McNamara,James H. McKerrow,James H. McKerrow,Jair L. Siqueira-Neto,Jair L. Siqueira-Neto +8 more
- 26 Mar 2020
TL;DR: Seven compounds of interest are identified with potent in vitro activity against the parasite with a therapeutic index of 10 or greater, including the previously unreported activity of the antiherpetic compound 348U87, providing the framework for further development of new T. cruzi leads that can potentially move quickly to the clinic.